The Union de pharmacologie scientifique appliquée (UPSA) is a French pharmaceutical group, independent from 1935 until acquisition by Bristol Myers Squibb in 1994.
[2] The Fondation Bru administers the charitable and cultural interests of the family.
In December 2018, Bristol-Myers announced the sale of UPSA to the Japanese group Taisho Pharmaceutical for $1.6 billion.
[7] On July 1, 2019, the sale of UPSA to Taisho Pharmaceutical is finalized.
However, UPSA retains its status as a company and its flagship brands remain manufactured in France on its site.